An interdisciplinary research team involving the German Center for Infection Research (DZIF) has identified two antiviral ...

AI and animation tech is used to create a broad-spectrum oral drug that blocks coronavirus entry, potentially preventing ...

Researchers at Harvard’s Wyss Institute for Biologically Inspired Engineering have developed a compound that could work as a ...

Influenza continues to pose a significant global health burden, with seasonal outbreaks causing substantial morbidity and ...

Multidisciplinary AI- and physics-driven modeling of the viral fusion process has enabled the discovery of an orally available drug inhibiting infection with multiple coronaviruses.

Our lead drug candidate is NV-387, a broad-spectrum antiviral drug that we plan to develop as a treatment of RSV, COVID, Long COVID, Influenza, and other respiratory viral infections, ...

Influenza continues to pose a significant global health burden, with seasonal outbreaks causing substantial morbidity and mortality. Current ...

SHELTON, CT / ACCESS Newswire / May 8, 2025 / NanoViricides, Inc. (NYSE Amer.:NNVC) (the "Company") today reported that it has received approval from the National Ethics Committee for Health (CNES ...

Broad-Spectrum Antiviral Drug NV-387 Cleared for Phase II Clinical Trial Application by the National Ethics Committee of the Democratic Republic of Congo ACCESS Newswire Updated May 8, 2025 5:41 AM ...